ES2180936T3 - Nuevos derivados de iridoide e inhibidores de la neovascularizacion que tienen como ingrediente activo dichos derivados. - Google Patents

Nuevos derivados de iridoide e inhibidores de la neovascularizacion que tienen como ingrediente activo dichos derivados.

Info

Publication number
ES2180936T3
ES2180936T3 ES97905448T ES97905448T ES2180936T3 ES 2180936 T3 ES2180936 T3 ES 2180936T3 ES 97905448 T ES97905448 T ES 97905448T ES 97905448 T ES97905448 T ES 97905448T ES 2180936 T3 ES2180936 T3 ES 2180936T3
Authority
ES
Spain
Prior art keywords
derivatives
active ingredient
vascularization
iridoid
neovascularization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905448T
Other languages
English (en)
Inventor
Hideaki Morishige
Yukiko Kurita
Yousuke Yamazaki
Chiaki Sakakibara
Masaharu Kigawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsumura and Co
Original Assignee
Tsumura and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura and Co filed Critical Tsumura and Co
Application granted granted Critical
Publication of ES2180936T3 publication Critical patent/ES2180936T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN NUEVOS DERIVADOS IRIDOIDES REPRESENTADOS POR LA FORMULA GENERAL (I): Y UN INHIBIDOR DE VASCULARIZACION QUE TIENE COMO PRINCIPIO ACTIVO DICHO DERIVADO. ESTE INHIBIDOR DE VASCULARIZACION PRESENTA UN NOTABLE EFECTO INHIBIDOR DE LA VASCULARIZACION SIN SERIOS EFECTOS SECUNDARIOS ADVERSOS, QUE ES UTIL EN EL TRATAMIENTO Y PREVENCION DE VARIAS ENFERMEDADES ACOMPAÑADAS POR UNA ACELERACION ANORMAL DE LA VASCULARIZACION.
ES97905448T 1996-03-06 1997-03-05 Nuevos derivados de iridoide e inhibidores de la neovascularizacion que tienen como ingrediente activo dichos derivados. Expired - Lifetime ES2180936T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7541996 1996-03-06

Publications (1)

Publication Number Publication Date
ES2180936T3 true ES2180936T3 (es) 2003-02-16

Family

ID=13575660

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905448T Expired - Lifetime ES2180936T3 (es) 1996-03-06 1997-03-05 Nuevos derivados de iridoide e inhibidores de la neovascularizacion que tienen como ingrediente activo dichos derivados.

Country Status (9)

Country Link
US (1) US6022888A (es)
EP (1) EP0889041B1 (es)
KR (1) KR19990087526A (es)
AT (1) ATE221073T1 (es)
AU (1) AU717878B2 (es)
CA (1) CA2248725A1 (es)
DE (1) DE69714230T2 (es)
ES (1) ES2180936T3 (es)
WO (1) WO1997032868A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69823866T2 (de) 1997-11-11 2005-05-19 The Kitasato Institute Substanz ft-0554 und verfahren zu ihrer herstellung
AUPR001000A0 (en) * 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US8790727B2 (en) * 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
EP1494662B1 (en) * 2002-04-11 2012-11-28 Children's Medical Center Corporation Tnp-470-hpma-methacrylic acid copolymer conjugates and use thereof
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
WO2004089926A2 (en) 2003-03-31 2004-10-21 Beth Israel Deaconess Medical Center, Inc. Genipin derivatives and uses thereof
US20050222053A1 (en) * 2003-10-31 2005-10-06 Health Research, Inc. Iridoid-saccharide compound and method of using same
US20080032939A1 (en) * 2004-10-28 2008-02-07 Health Research, Inc. Iridoid-saccharide compound and method of using same
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
JP5142311B2 (ja) * 2006-10-26 2013-02-13 小林製薬株式会社 ゲニポシド酸誘導体
WO2009137337A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations
US20120021079A1 (en) * 2010-02-23 2012-01-26 Brett Justin West Garcinia Mangostana L. and Iridoid Based Formulations
WO2014165023A1 (en) * 2013-03-12 2014-10-09 Carnegie Mellon University Coated vaso-occclusive device for treatment of aneurysms
FR3003860B1 (fr) * 2013-03-29 2015-11-27 Oreal Composes derives d'iridoides proteges ou non, composition les comprenant, utilisation comme colorant des fibres keratiniques et dispositifs
CN104892562B (zh) * 2015-06-16 2017-03-15 吴虹 抑制环氧化酶‑2的化合物及其制备方法和应用
CN107400128B (zh) * 2017-07-27 2020-03-31 贵州省中国科学院天然产物化学重点实验室 拟单萜吲哚生物碱及其制备方法和应用
US12201315B2 (en) 2017-10-16 2025-01-21 Retriever Medical, Inc. Clot removal methods and devices with multiple independently controllable elements
US10258357B1 (en) 2017-10-16 2019-04-16 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
WO2022082213A1 (en) 2017-10-16 2022-04-21 Retriever Medical, Inc. Clot removal methods and devices with multiple independently controllable elements
KR20230049089A (ko) * 2020-08-12 2023-04-12 잉크박스 잉크 인코포레이티드 반영구 문신
CA3239950A1 (en) * 2021-12-07 2023-06-15 Christopher B. Caputo Compounds attachable to skin
CN115572278B (zh) * 2022-11-21 2023-09-01 北京志道生物科技有限公司 京尼平衍生物及其制备方法和应用
CN118834253B (zh) * 2024-06-25 2025-03-18 南开大学 京尼平苷衍生物和京尼平衍生物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617555C3 (de) * 1966-04-19 1974-09-19 Kali-Chemie Ag, 3000 Hannover Verfahren zur Isolierung von therapeutisch wertvollen Isovaleriansäureestern aus Valeriana- und Kentranthus-Extrakten
US4205083A (en) * 1968-03-30 1980-05-27 Kali-Chemie Aktiengesellschaft Cyclopentapyrans
DE3026579A1 (de) * 1980-07-14 1982-02-11 Kali-Chemie Pharma Gmbh, 3000 Hannover 2,9-dioxatricyclo (4,3,1,o(pfeil hoch)3,7(pfeil hoch)) decane
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
EP0505572A4 (en) * 1990-10-09 1993-03-10 Tsumura & Co. Iridoide derivative and its use as medicine
KR100218052B1 (ko) * 1992-07-15 1999-09-01 이병언 B형 간염 바이러스의 복제를 억제하는 약학적 제제

Also Published As

Publication number Publication date
EP0889041A1 (en) 1999-01-07
EP0889041A4 (en) 2000-08-23
DE69714230T2 (de) 2003-03-27
KR19990087526A (ko) 1999-12-27
ATE221073T1 (de) 2002-08-15
EP0889041B1 (en) 2002-07-24
AU2231797A (en) 1997-09-22
US6022888A (en) 2000-02-08
CA2248725A1 (en) 1997-09-12
AU717878B2 (en) 2000-04-06
DE69714230D1 (de) 2002-08-29
WO1997032868A1 (en) 1997-09-12

Similar Documents

Publication Publication Date Title
DE69714230D1 (de) Neue iridoidderivate und neovaskularisations-inhibitoren die diese als aktviven inhaltstoff enthalten
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
EP0795548A4 (en) CHINAZOZINE DERIVATIVES AND THEIR USE
MXPA04012965A (es) Inhibidores virales.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ATE511858T1 (de) 2,4,6-triamino-1,3,5-triazin-derivat
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
PT1447399E (pt) Derivado de 2-oxo-1-pirrolidina e as suas utilizacoes farmaceuticas
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
PT1037886E (pt) Inibidores de angiogenese de triazina
AU2406402A (en) Substituted benzene derivatives or salts thereof
AU2002342878A1 (en) Pyridylpyrimidine derivatives as effective compounds against prion diseases
EP1208092A4 (en) SULPHONAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
ES2131373T3 (es) Composicion oftalmica para prevenir o tratar el ojo seco o una enfermedad causada por el mismo, que comprende acido 12-sulfodeshidroabietico.
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
ES2184097T3 (es) Nuevos compuestos.
EE04564B1 (et) Bifenlamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning proflaktiline ja terapeutiline toimeaine tromboosi v?i emboolia vastu
DK0729753T3 (da) Anvendelse af dioxabicyclo(3.3.0)octaner til behandling af forebyggelse af cerebral apopleksi
ES2171945T3 (es) Derivados aromaticos de amidina que sirven de inhibidores selectivos de la trombina.
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
BR9608413A (pt) Inibidor de edema cerebral
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
HN1997000070A (es) Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos
DK0966283T3 (da) Farmaceutiske præparater til helbredelse og forebyggelse af sygdomme, som stammer fra beskadigelse af vaskulære endotelceller
DE60034545D1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung